Toxic Encephalopathy After Relapsed Indolent Non-Hodgkin’s Lymphoma Following Abrupt Discontinuation of Idelalisib (ZYDELIG®)

Idelalisib is a delta isoform-specific, phosphoinositide 3-kinase (PI3-K) inhibitor. It has been used as a single agent for the treatment of relapsed or refractory small lymphocytic lymphoma (SLL), follicular non-Hodgkin’s lymphoma (NHL), and in combination with rituximab for patients with chronic l...

Descripción completa

Detalles Bibliográficos
Autores principales: Shenouda, Mina, Urella, Madhulika, Assad, Salman, Dotson, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2019
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6464486/
https://www.ncbi.nlm.nih.gov/pubmed/31016071
http://dx.doi.org/10.7759/cureus.4043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6464486/
https://www.ncbi.nlm.nih.gov/pubmed/31016071
http://dx.doi.org/10.7759/cureus.4043

Ejemplares similares